Sareum - Specialists in Cancer Drug Discovery
Print the page Smaller text Larger text

 

UK Pharmaceutical Company
15 December, 2004

Cancer Research Technology
06 December, 2004

Sareum & EiRx
01 December, 2004

Millennium Pharmaceuticals
22 November, 2004

Inpharmatica Collaboration
09 November, 2004

Sareum Admission to AIM
11 October, 2004

Board Appointments
15 September, 2004

 

Previous releases

2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004

RSS news feed News feed
requires RSS news reader

Board Appointments

Cambridge, UK - 15 September, 2004: Sareum Limited, the protein structure-based drug discovery company, today announces the appointments of Dr Paul Harper as non-executive Chairman, Mr Edward Oliver as Finance Director and Dr Alan Lamont as non-executive Director.

Dr Paul Harper has over thirty years experience of the life sciences industry covering both drug development and medical devices. Paul has served as Chief Executive of Cambridge Antibody Technology Limited, and Provensis Limited. He has also served as Corporate Development Director of Unipath Limited, then the medical diagnostics business of Unilever plc and as Director of Research and Development for Johnson & Johnson Limited. Formerly head of Antimicrobial Chemotherapy for Glaxo Group Research Limited, Paul Harper holds a doctorate in Molecular Virology and is the author of over 50 publications.

Edward Oliver is a Chartered Accountant with considerable experience both in professional practice and in industry. Formerly a senior partner at the London based firm of Chartered Accountants, AGN Shipleys, Edward has since 2002 provided consultancy and advisory services to companies through his firm, Olivers. Edward is also finance director of Zyzygy, a substantial shareholder in Sareum Holdings plc.

Dr Alan Lamont has over sixteen years experience in the pharmaceuticals sector covering both research, and business development. Alan is currently the Vice President of Business Development at Acambis plc where he develops and finalises deals and collaborations for both inlicensing and out-licensing. Prior to this role he was Business Development Manager at Catalyst BioMedica Limited (a subsidiary of the Wellcome Trust) and Director of Biology at Peptide Therapeutics plc with previous senior positions at Roche Products Limited, Cantab Pharmaceuticals plc and Cytel Corp. Inc. Alan holds a doctorate in Immunology and Physiology.

Commenting on the appointments, Dr. Tim Mitchell, CEO of Sareum, said: "I am delighted to welcome Paul, Edward and Alan to the Sareum Board. Between them they bring tremendous industry, finance and business experience to the company and will make invaluable contributions to our success."

For further information, please contact: Dr Tim Mitchell +44 (0) 1223 497 700



Requires RSS news reader

Requires MS Word

Requires Adobe Acrobat Reader


site map

cookie policy

email: info (at) sareum.co.uk tel: +44 (0) 1223 497700 fax: +44 (0) 1223 497701